From the Turning Point, Eastern Health, Melbourne, Victoria, Australia (AJR, JAN, SA); National Drug and Alcohol Research Centre, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia (AJR); The National Centre for Clinical Research on Emerging Drugs, University of New South Wales, Sydney, New South Wales, Australia (AJR); Department of Psychology, Towson University, Towson, MD, United States (ECK): Monash Alfred Psychiatry Research Centre, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (SA).
Received for publication August 3, 2021; accepted May 15, 2022.
Supported by a fellowship from the National Centre for Clinical Research in Emerging Drugs (NCCRED), funded by the Commonwealth Department of Health (Australia). NCCRED had no role in the design of the review, analysis, interpretation, writing the manuscript, or the decision to submit the paper for publication.
The authors report no conflicts of interest.
Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.journaladdictionmedicine.com).
Send correspondence to Adam James Rubenis, DPsych, 110 Church St, Richmond 3121, Victoria, Australia. E-mail: [email protected].